Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Explore this paper's citation graph
Summary
The study depicts binding of chemotherapeutic drugs to CYP3A4 and has identified the residues that may be targeted for therapy in NSCLC patients.
- Type
- article
- Published
- 2015-07-01
- Cited by
- 24
- References
- 96
- OpenAlex
- https://openalex.org/W616667036
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41435196
Keywords
Gemcitabine, Carboplatin, Docetaxel, Paclitaxel, Docking (animal)
References
- Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.
- The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis.
- Drug metabolism and variability among patients in drug response.
- Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel
- Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma
- Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients
- Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
- Expression of cytochromes P450 in human breast tissue and tumors.
- Cytochrome P450 enzymes and tumor therapy.
- Mechanism-based pharmacokinetic model for paclitaxel.
- Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
- Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
- Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma*
- Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
- The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons.
- Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.
- Pharmacogenomics: Application to the Management of Cardiovascular Disease
- Moving towards individualized medicine with pharmacogenomics
- Expression of CYP3A4 in human breast tumour and non-tumour tissues.
- Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Cited by
- Pharmacogenomics Influencing Drug-Gene Interactions Leading Towards Personalized Medicine
- Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARγ
- Insilco Modeling of Commonly Occurring Genetic Polymorphism of Human CYP3A4 on the Binding Affinity to UR-144
- Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay.
- Trans-anethole ameliorates obesity via induction of browning in white adipocytes and activation of brown adipocytes.
- Screening and identification of novel inhibitors against human 4-aminobutyrate-aminotransferase: A computational approach
- Nanogold-core multifunctional dendrimer for pulsatile chemo-, photothermal- and photodynamic- therapy of rheumatoid arthritis.
- Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach
- Ginsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization
- Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database
- Structural and vibrational investigations and molecular docking studies of a vinca alkoloid, vinorelbine
- A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs.
- Gemcitabine enhances pharmacokinetic exposure of the major components of Danggui Buxue Decoction in rat via the promotion of intestinal permeability and down-regulation of CYP3A for combination treatment of non-small cell lung cancer
- Computational predictions of site of metabolism of a pyrrolebased compound as a potential antitubercular agent
- Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers.
- Exploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function
- Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer
- How Plant Polyhydroxy Flavonoids Can Hinder the Metabolism of Cytochrome 3A4
- Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy
- In silico and in vitro studies of gemcitabine derivatives as anticancer agents
Related papers
- Experimental study of different platinum alone or combined with taxanes or vinorelbine against lung cancer cell lines in vitro
- 進行非小細胞肺癌に対するCarboplatin＋Paclitaxel後Gemcitabine療法とCarboplatin＋Gemcitabine後Docetaxel療法の無作為第 ＩＩ 相試験
- PCN13: PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN
- Clinical Response of Docetaxel Plus Cisplatin and Paclitaxel Plus Carboplatin Chemotherpy in Non-Small Cell Lung Cancer.
- Pharmacoeconomic analysis of advanced non-small cell lung cancer treatment with docetaxel-cisplatin, paclitaxel-cisplatin and paclitaxel-carboplatin
- Combining two different chemotherapy agents with platinum analogs as induction and consolidation regimes in nonsmall cell lung carcinoma
- Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
- Improved Outcomes With Carboplatin-Paclitaxel Compared to Docetaxel-Cisplatin-5-Fluorouracil Induction Chemotherapy in Locally-Advanced Squamous Cell Cancer of the Head and Neck
- Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
- Chemotherapeutic Agents Increase PD-L1 Expression in A549 Lung Cancer Cell Line